Schedule 13G ownership disclosure
CHECKPOINT THERAPEUTICS INC
Common Stock, par value $0.0001 per share · CUSIP: 162828206
Event date: 2025-03-10
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Glazer Capital, LLC
Shares: 3,087,052.00 · Class: 6.41%
- Paul J. Glazer
Shares: 3,087,052.00 · Class: 6.41%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001076809-25-000033
- Form type
- SCHEDULE 13G
- Filer
- Checkpoint Therapeutics, Inc.
- CIK
- CIK 1651407
- Filed
- Mar 17, 2025
- Reporting period
- Mar 10, 2025
- Description
- Schedule 13G beneficial ownership